Jefferies maintained Boston Scientific Corporation (NYSE: BSX ) with a Hold rating and raised the price target from $7.60 to $8.30. Jefferies noted, "Echoing a common refrain in medtech these days, the message from Boston's investor day was that stabilizing core markets and a concerted effort to diversify away from